NCT01536028 - Comparison of the Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30, 50, 70 and Insulin Aspart in Subjects With Type 1 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

July 31, 2006

Study Completion Date

July 31, 2006

Conditions

DiabetesDiabetes Mellitus, Type 1

Interventions

DRUG

biphasic insulin aspart 30

A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between

DRUG

biphasic insulin aspart 50

A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between

DRUG

biphasic insulin aspart 70

A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between

DRUG

insulin aspart

A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between

Trial Locations (1)

41460

Novo Nordisk Investigational Site, Neuss